Bystander T cells can enhance antitumor effects of bispecific antibody

T-cell redirection therapy using chimeric antigen receptor (CAR) T cells and/or bispecific antibody (BsAb) has been established and become a promising treatment strategy for relapsed/refractory B-cell lymphomas. To further improve their therapeutic efficacy, assessment of their in vivo mechanisms and the ways of sequential approaches are necessary.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup